DENVER, Colo. (247marketnews.com) -- Glucotrack (NASDAQ:GCTK) continues to broaden its healthcare platform beyond diabetes technology, announcing a meaningful development for its wholly owned biopharmaceutical subsidiary, Lōkahi Therapeutics, and its lead therapeutic candidate, LT-100. While Glucotrack is widely recognized for developing its long-term implantable continuous blood glucose monitoring (CBGM) system, the company is simultaneously advancing a second growth initiative through Lōkahi, which focuses on acquiring and developing overlooked therapeutic assets.
The latest update centers on LT-100, where management is pursuing what could become a significant improvement in patient convenience. Historically, LT-100 has been administered through up to 15 intradermal injections during a single treatment visit. Lōkahi is now evaluating whether that regimen can be replaced with a single subcutaneous injection, potentially making treatment substantially simpler if clinical studies support the approach.
The strategy gained momentum following a Type C meeting with the U.S. Food and Drug Administration (FDA) in May 2026, during which the company discussed its proposed clinical development pathway. Following that regulatory interaction, Lōkahi completed a nonclinical minipig study comparing systemic drug exposure between intradermal and subcutaneous administration. According to the company, the study generated information supporting its planned clinical evaluation of the simplified dosing strategy.
Management now expects to begin clinical evaluation of the single-injection approach as early as the fourth quarter of 2026, subject to ongoing development work and regulatory review. An initial clinical readout could potentially follow during the first half of 2027, providing investors with another important milestone to monitor.
The announcement also highlights Lōkahi's broader business model. Rather than building an entirely new drug pipeline from scratch, the company seeks to identify promising but underdeveloped therapeutic assets and advance them through a capital-efficient development strategy supported by its proprietary ai² platform and ai² Futures Lab framework. If successful, this model could allow Glucotrack to diversify its long-term value drivers beyond medical devices into therapeutics.
Sources
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.